Regionshospitalet Viborg
- Address
- lock Available on a paid plan
Regionshospitalet Viborg - Headache and Migraine Research
Regionshospitalet Viborg is actively engaged in clinical research focusing on neurological conditions, with particular expertise in migraine management and acute headache treatment. The center participates in Phase 4 clinical trials evaluating innovative therapeutic approaches for patients who have limited treatment options.
- Acute migraine treatment strategies for patients unsuitable for conventional therapies
- Evaluation of novel CGRP antagonists and their efficacy in migraine pain relief
- Assessment of treatment tolerability and safety profiles in diverse migraine patient populations
The research center specializes in investigating migraine attacks with or without aura, conducting rigorous randomized, double-blind, placebo-controlled trials to establish evidence-based treatment protocols. Their work focuses on identifying effective alternatives for patients who cannot tolerate or have contraindications to triptan medications, thereby expanding therapeutic options for underserved migraine populations and improving patient outcomes through carefully designed clinical efficacy studies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Region Hovedstaden1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Region Hovedstaden2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Regionshospitalet Viborg
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome | Janssen Cilag International | Phase III | Not Recruiting | Nov 2023 | Jan 2026 |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 2 | Unknown | 2023-11-21 | 2023-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.